Share Name Share Symbol Market Type Share ISIN Share Description
Skinbiotherap. LSE:SBTX London Ordinary Share GB00BF33H870 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 9.50p 9.00p 10.00p 9.50p 9.50p 9.50p 0 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -0.7 -1.1 - 11.28

Skinbiotherap. Share Discussion Threads

Showing 1226 to 1250 of 1250 messages
Chat Pages: 50  49  48  47  46  45  44  43  42  41  40  39  Older
DateSubjectAuthorDiscuss
20/1/2018
07:53
JamgrO From Nov 2017 hTTps://tinyurl.com/y8ehcn2r The firm is developing three products that manage, protect and restore the body’s outer layer. First cab off the rank will be the company’s cosmetic for sensitive skin, which should be properly formulated towards the end of this year, before entering human studies in the second-quarter of next. Going into development in the third-quarter of next year is a prophylactic for healthcare acquired infections. The company hopes to begin commercialising the protective hand cream in 2020, the same year as work begins on an eczema treatment.
parob
20/1/2018
00:03
In articles and RNS's....look them up and DYOR.
bobalot
19/1/2018
12:17
Bobalot - where did you manage to find that info? I knew they were scheduled for 2018 with the trial designs already in place but must have missed that nugget of info
jamgr0
19/1/2018
09:14
Thanks again, will be interesting to see if they are brought forward.
rafboy
19/1/2018
09:06
The human trials were planned to start in Q2. Which means from April onwards.
bobalot
19/1/2018
08:43
Thanks bobalot, I knew about the duration but the start date is what I am really interested in. I agree these will be inflexion points.
rafboy
19/1/2018
08:33
Possibly from April..it will only take a month then the company hand-over to a commercial partner for product registration and commercialisation. And those activities are the inflexion points when the share price should takeoff imo.
bobalot
18/1/2018
15:49
If possible can someone obtain an approximation of when the human trials will start. Thanks.
rafboy
18/1/2018
15:12
Dr David Moyes has done well after leaving Everton!
rafboy
18/1/2018
13:40
One would have thought a better venue would have been in London, I don’t travel well up north in the winter😉
ny boy
12/1/2018
20:57
SkinBioTherapeutics Retweeted Alice Vickers‏ @AliceVickers5 @KCL_IF will be exploring 'Innovations in the Microbiome' with Prof @timspector, Dr Penny Wilson (@innovateuk), Dr Catherine O'Neil (@SkinBioT) and Dr Judith Fernandez-Piquer (@Unilever) on 21st Feb. Tickets available here hTTps://www.eventbrite.co.uk/e/innovation-in-the-microbiome-tickets-39791960826 Agenda: Registration - 6:00-6:30pm Introduction from Innovation Forum- 6:30-6:35pm Opening Keynote - 6:35-6:45pm Dr Penny Wilson - Senior Specialist in AMR, Vaccines and Global Health at Innovate UK Advances in the Microbiome - 6:45-7:45pm Prof Tim Spector - Professor of Genetic Epidemiology, Director of TwinsUK at King's College London & Author Dr Catherine O'Neill - CEO of SkinBioTherapeutics Dr David Moyes - Lecturer in Host-Microbiome Interactions, King's College London Dr Judith Fernandez-Piquer - Scientist at the Safety & Environmental Assurance Centre, Unilever
parob
12/1/2018
19:36
It depends if you need to sit an interview in Liverpool.
elrico
12/1/2018
16:45
elrico - How long will it take us southerners to get a visa for Manchester?
asterix96
12/1/2018
16:08
@ 7 miles from kennel, I guess you're correct. Btw, anyone interested in putting faces to usernames, inbox me. Just don't ask me to wear a rose. I suspect most PI's are southerly and fearful of venturing to Madchester.
elrico
12/1/2018
15:35
I'd have thought you could walk there, elrico !
luminoso
12/1/2018
14:04
Parking is a tad steep. Dear Elric, Thank you for registering to the event. It is a pleasure to welcome you as a delegate to the Shares Investor Evening which will take place at the Macdonald Manchester Hotel on Tuesday 20 February 2018. Please PRINT and bring this email to the Investor Evening delegate registration desk on the day as we will scan your personal barcode. Alternatively you can show us your barcode from your smart phone or tablet. Registration commences at 17:45. Tea/coffee will be served from 17:45 to 18:15. Presentations will start at 18:15 sharp and finish at 20:30. They will be followed by a drinks reception. Venue details: Macdonald Manchester Hotel Meeting Room 11 London Road Manchester M1 2PG Transport: 0.3 miles from Manchester Picadilly Station 10.5 miles from Manchester Airport If traveling by car please use M1 2AD which will direct you the hotel’s car park on Berry Street. Please note the fee to park at the hotel will be £15.00.
elrico
12/1/2018
13:57
I've registered.
elrico
12/1/2018
07:56
Shares Investor Evening (Manchester) - 20 Feb 2018 hTTps://www.sharesmagazine.co.uk/events/event/shares-investor-evening-manchester-200218 Companies presenting: SkinBioTherapeutics (SBTX) - SkinBioTherapeutics is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix, is based upon discoveries made by CEO Dr. Catherine O’Neill and Professor Andrew McBain at The University of Manchester. The SkinBioTherapeutics’ platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, improve repair and reduce bacterial load. SkinBioTherapeutics is targeting three specific skin healthcare sectors; cosmetics, infection control and eczema. In each of these areas Skin BioTherapeutics plans to exemplify its technology in human studies. The most advanced programme is focused on the application of the Skinbiotix® platform in managing sensitive skin in the cosmetics industry. The business strategy is to partner and outlicense its programmes at proof of concept.
parob
05/1/2018
15:50
Interesting year ahead. Glad I topped up when I did.
rafboy
05/1/2018
14:16
SkinBioTherapeutics‏ tweet just now: "Microbiome Clinical Studies Loom Large In 2018" - very interesting article by @ScripJohnD about recent developments in the #microbiome field and what to expect in 2018. @PharmaScrip hTTps://scrip.pharmaintelligence.informa.com/SC100142/Microbiome-Clinical-Studies-Loom-Large-In-2018
parob
05/1/2018
13:45
Hopefully not, they had 3.9 million in June and its not a high cash burn company.
eekorehc
05/1/2018
13:11
Slight concern the joint broker may signal an imminent discounted placing
onedayrodders
05/1/2018
10:43
Joint broker announced, not sure what benefit that adds apart from double the cost. Someone more enlightened can fill in the blanks here...
rathean
04/1/2018
19:21
Parob I am sure we will both do well.
rafboy
04/1/2018
16:48
Joined you for a few today rafboy and paid 9p so well done on your 8.5p purchase! Although I did manage to grab a few when it hit that price last time round. N4P wasn't a much loved stock for months and bobbed around the 5/6p mark for a while before sharply moving North. Can see the same thing happening here.
parob
Chat Pages: 50  49  48  47  46  45  44  43  42  41  40  39  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20180120 09:14:38